Eledon Pharmaceuticals appoints James Robinson to board effective Oct 1, 2023

Eledon Pharmaceuticals, Inc.

Robinson will serve as chair of the Compensation Committee and member of Audit Committee.
Annual cash retainers of $42k for board service, $15.75k as comp chair, $10.5k for audit committee.
Granted option to purchase 150,437 shares vesting over two years at market price on grant date.
Board determined Robinson qualifies as independent under Nasdaq rules; no family relationships or arrangements.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Robinson

director

ELDN · Eledon Pharmaceuticals, Inc.

Effective: 2023-10-01
Filed: September 13, 2023, 7:59 PM ET

On September 11, 2023, James Robinson was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Robinson was appointed as director at Eledon Pharmaceuticals, Inc..

Action: appointed
Role: director

Exact text from the filing

On September 11, 2023, James Robinson was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 1, 2023.

View on SEC.gov

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-047951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.